- Drs. Daniel C. Cattran and
Fernando C. Fervenza join ZyVersa's
distinguished group of Scientific Advisors
- VAR 200 is a phase 2a-ready cholesterol efflux mediator in
development to ameliorate renal lipid accumulation that damages the
kidneys' filtration system, leading to progression of kidney
disease
WESTON,
Fla., Jan. 3, 2023 /PRNewswire/ -- ZyVersa
Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage
specialty biopharmaceutical company developing first-in-class drugs
for treatment of renal and inflammatory diseases, announces that
two leading nephrologists have joined ZyVersa's Renal Scientific
Advisory Board.
Two esteemed nephrologists join ZyVersa's
Renal Scientific Advisory Board, Drs. Daniel C. Cattran & Fernando C. Fervenza
Daniel C. Cattran,
MD
Professor of Medicine, University of Toronto
Senior Scientist, Toronto General
Research Institute
Fernando C. Fervenza, MD,
PhD
Professor of Medicine, Mayo
Graduate School of Medicine
Director of the Nephrology Collaborative Group
"We are honored that nephrologists with the accomplishments of
Drs. Cattran and Fervenza are joining our Scientific Advisory
Board," stated Dr. Pablo Guzman,
ZyVersa's Chief Medical Officer, and Chairman of the Renal
Scientific Advisory Board. "Their clinical and research expertise
have earned them global distinction as key thought-leaders in the
field of nephrology. We look forward to their invaluable
contributions that will help drive the timely success of our
clinical development program for our cholesterol efflux mediator,
VAR 200," continued Dr. Guzman.
Drs. Cattran and Fervenza join ZyVersa's current team of
prominent Scientific Advisors, Sharon G.
Adler, MD: Professor of Medicine at David Geffen School
of Medicine, UCLA; Chief, Division of
Nephrology and Hypertension at Harbor-UCLA Medical Center; and
Program Director, Nephrology Fellowship Training Program at
Harbor-UCLA Medical Center; Alessia
Fornoni, MD, PhD: Professor of Medicine and Chief of
Katz Family Division of Nephrology and Hypertension at University of Miami Miller School of Medicine;
Debbie S. Gipson, MD, MS:
Professor, Department of Pediatrics at University of Michigan and Director of the Kidney
Research Network Coordinating Center; Marlene Haffner, MD, MPH: Principal and
Founder of Orphan Solutions and former Director of Orphan Products
Development at FDA; and Pablo A.
Guzman, MD, FAAC: Chief Medical Officer and Chairman of
Renal Scientific Advisory Board at ZyVersa Therapeutics.
"Enlisting the insights and strategic guidance of our renowned
scientific advisory board is key to achieving our mission to
develop transformative drug therapies for patients with renal
disease," said Stephen C. Glover,
ZyVersa's Co-founder, Chief Executive Officer, and Chairman. "We
appreciate their expertise and time to support our mission," added
Mr. Glover.
About VAR 200
VAR 200 (2-hydroxypropyl-beta-cyclodextrin, 2HPβCD) is a
cholesterol efflux mediator in development to ameliorate renal
lipid accumulation that damages the kidneys' filtration system,
leading to kidney disease progression. VAR 200 passively and
actively removes excess lipids from the kidney.
Preclinical studies with VAR 200 in animal models of FSGS,
Alport syndrome, and diabetic kidney disease demonstrate that
removal of excess cholesterol and lipids from kidney podocytes
protects against structural damage and reduces excretion of protein
in the urine (proteinuria).
The lead indication for VAR 200 is orphan kidney disease focal
segmental glomerulosclerosis (FSGS). VAR 200 has potential to treat
other glomerular diseases, including orphan Alport syndrome and
diabetic kidney disease.
About ZyVersa Therapeutics,
Inc.
ZyVersa is a clinical stage specialty biopharmaceutical company
leveraging advanced, proprietary technologies to develop
first-in-class drugs. Our focus is on patients with renal or
inflammatory diseases who have significant unmet medical needs. Our
development pipeline includes phase 2a-ready VAR 200, a cholesterol
efflux mediator in development to alleviate damaging accumulation
of cholesterol and lipids in the filtering system of the kidneys.
The lead indication is treatment of rare kidney disease, focal
segmental glomerulosclerosis. VAR 200 has potential to treat other
kidney diseases, including Alport syndrome and diabetic kidney
disease. Our pipeline also includes a proprietary
inflammasome ASC inhibitor that blocks initiation and
perpetuation of damaging inflammation associated with a multitude
of inflammatory diseases. IC 100 has potential to treat many
different CNS and other inflammatory diseases. For more
information, please visit www.zyversa.com.
Cautionary Statement Regarding
Forward-Looking Statements
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management's intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc ("ZyVersa") uses words such as
"anticipates," "believes," "plans," "expects," "projects,"
"future," "intends," "may," "will," "should," "could," "estimates,"
"predicts," "potential," "continue," "guidance," and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa's expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa's plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa's planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa's preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa's plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa's product candidates; ZyVersa's
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa's ability to protect its intellectual property
position; and ZyVersa's estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/zyversa-therapeutics-adds-two-esteemed-leaders-in-nephrology-to-its-renal-scientific-advisory-board-to-support-clinical-advancement-of-lead-renal-drug-candidate-var-200-301712084.html
SOURCE ZyVersa Therapeutics, Inc.